
|Videos|April 29, 2011
Dr. Karlan Describes AMG 386 Side Effects
Author(s)Beth Y. Karlan MD
Dr. Karlan Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial
Advertisement
Beth Y. Karlan MD, a Director at Cedars-Sinai Women's Cancer Research Institute Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5




































